Cargando…
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
Malignant peritoneal mesothelioma (MPM) is an aggressive rare malignancy associated with asbestos exposure. A better understanding of the molecular pathogenesis of MPM will help develop a targeted therapy strategy. Oncogene targeted depth sequencing was performed on a tumor sample and paired periphe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881561/ https://www.ncbi.nlm.nih.gov/pubmed/27187383 http://dx.doi.org/10.3390/ijms17050739 |
_version_ | 1782433985713930240 |
---|---|
author | Lai, Jun Zhou, Zhan Tang, Xiao-Jing Gao, Zhi-Bin Zhou, Jie Chen, Shu-Qing |
author_facet | Lai, Jun Zhou, Zhan Tang, Xiao-Jing Gao, Zhi-Bin Zhou, Jie Chen, Shu-Qing |
author_sort | Lai, Jun |
collection | PubMed |
description | Malignant peritoneal mesothelioma (MPM) is an aggressive rare malignancy associated with asbestos exposure. A better understanding of the molecular pathogenesis of MPM will help develop a targeted therapy strategy. Oncogene targeted depth sequencing was performed on a tumor sample and paired peripheral blood DNA from a patient with malignant mesothelioma of the peritoneum. Four somatic base-substitutions in NOTCH2, NSD1, PDE4DIP, and ATP10B and 1 insert frameshift mutation in BAP1 were validated by the Sanger method at the transcriptional level. A 13-amino acids neo-peptide of the truncated Bap1 protein, which was produced as a result of this novel frameshift mutation, was predicted to be presented by this patient’s HLA-B protein. The polyclonal antibody of the synthesized 13-mer neo-peptide was produced in rabbits. Western blotting results showed a good antibody-neoantigen specificity, and Immunohistochemistry (IHC) staining with the antibody of the neo-peptide clearly differentiated neoplastic cells from normal cells. A search of the Catalogue of Somatic Mutations in Cancer (COSMIC) database also revealed that 53.2% of mutations in BAP1 were frameshift indels with neo-peptide formation. An identified tumor-specific neo-antigen could be the potential molecular biomarker for personalized diagnosis to precisely subtype rare malignancies such as MPM. |
format | Online Article Text |
id | pubmed-4881561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48815612016-05-27 A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma Lai, Jun Zhou, Zhan Tang, Xiao-Jing Gao, Zhi-Bin Zhou, Jie Chen, Shu-Qing Int J Mol Sci Article Malignant peritoneal mesothelioma (MPM) is an aggressive rare malignancy associated with asbestos exposure. A better understanding of the molecular pathogenesis of MPM will help develop a targeted therapy strategy. Oncogene targeted depth sequencing was performed on a tumor sample and paired peripheral blood DNA from a patient with malignant mesothelioma of the peritoneum. Four somatic base-substitutions in NOTCH2, NSD1, PDE4DIP, and ATP10B and 1 insert frameshift mutation in BAP1 were validated by the Sanger method at the transcriptional level. A 13-amino acids neo-peptide of the truncated Bap1 protein, which was produced as a result of this novel frameshift mutation, was predicted to be presented by this patient’s HLA-B protein. The polyclonal antibody of the synthesized 13-mer neo-peptide was produced in rabbits. Western blotting results showed a good antibody-neoantigen specificity, and Immunohistochemistry (IHC) staining with the antibody of the neo-peptide clearly differentiated neoplastic cells from normal cells. A search of the Catalogue of Somatic Mutations in Cancer (COSMIC) database also revealed that 53.2% of mutations in BAP1 were frameshift indels with neo-peptide formation. An identified tumor-specific neo-antigen could be the potential molecular biomarker for personalized diagnosis to precisely subtype rare malignancies such as MPM. MDPI 2016-05-14 /pmc/articles/PMC4881561/ /pubmed/27187383 http://dx.doi.org/10.3390/ijms17050739 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lai, Jun Zhou, Zhan Tang, Xiao-Jing Gao, Zhi-Bin Zhou, Jie Chen, Shu-Qing A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma |
title | A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma |
title_full | A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma |
title_fullStr | A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma |
title_full_unstemmed | A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma |
title_short | A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma |
title_sort | tumor-specific neo-antigen caused by a frameshift mutation in bap1 is a potential personalized biomarker in malignant peritoneal mesothelioma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881561/ https://www.ncbi.nlm.nih.gov/pubmed/27187383 http://dx.doi.org/10.3390/ijms17050739 |
work_keys_str_mv | AT laijun atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT zhouzhan atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT tangxiaojing atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT gaozhibin atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT zhoujie atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT chenshuqing atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT laijun tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT zhouzhan tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT tangxiaojing tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT gaozhibin tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT zhoujie tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma AT chenshuqing tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma |